/Abbvie%20Inc%20logo%20and%20stock%20chart-by%20IgorGolovniov%20via%20Shutterstock.jpg)
With a market cap of $309.7 billion, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company, engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. Based in North Chicago, Illinois, the company’s offerings include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta/Venclyxto, and others.
The company is expected to report its Q1 earnings on Friday, Apr. 25, before the market opens. Ahead of the event, analysts expect ABBV to report an EPS of $2.38 per share, up 3% from $2.31 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in all of the past four quarters. Its adjusted EPS of $2.16 in the recent quarter surpassed analysts’ expectations by 1.4%, driven by a solid performance in its Immunology, Oncology, Neuroscience, and Aesthetics portfolio.